Recent evidence from pre-clinical and clinical observations, indicate that β2AR- selective antagonists as well as non-subtype selective antagonists can ameliorate pathological angiogenesis in infantile hemangiomas and proliferative retinopathy [10–14]. Here, ADRB2 is linked to retinal disorder.